Repligen (NASDAQ:RGEN) Shares Gap Down – Should You Sell?

Repligen Corporation (NASDAQ:RGEN)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $145.49, but opened at $131.95. Repligen shares last traded at $137.0930, with a volume of 451,431 shares traded.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RGEN shares. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research note on Tuesday, July 7th. HSBC dropped their price target on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Citigroup upgraded shares of Repligen to a “buy” rating in a research note on Tuesday, July 7th. Rothschild & Co Redburn set a $160.00 target price on shares of Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Finally, Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 14th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $165.00.

Repligen Trading Down 7.7%

The business has a 50-day moving average price of $129.28 and a 200-day moving average price of $133.14. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $7.57 billion, a P/E ratio of 148.98, a PEG ratio of 2.84 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.25 million for the quarter, compared to the consensus estimate of $192.05 million. During the same quarter in the previous year, the company earned $0.39 earnings per share. The business’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wasatch Advisors LP raised its position in Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after purchasing an additional 346,720 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Repligen by 11.8% in the second quarter. Handelsbanken Fonder AB now owns 22,070 shares of the biotechnology company’s stock valued at $3,011,000 after buying an additional 2,332 shares during the last quarter. Everhart Financial Group Inc. bought a new position in shares of Repligen in the second quarter valued at about $303,000. Assenagon Asset Management S.A. acquired a new position in Repligen during the 2nd quarter worth about $9,687,000. Finally, Balefire LLC bought a new stake in Repligen during the 2nd quarter worth about $275,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.